High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials

PURPOSE: Adjuvant high-dose chemotherapy (HDC) with autologous hematopoietic stem-cell transplantation (AHST) for high-risk primary breast cancer has not been shown to prolong survival. Individual trials have had limited power to show overall benefit or benefits within subsets. METHODS: We assembled...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Berry, Donald A., Ueno, Naoto T., Johnson, Marcella M., Lei, Xiudong, Caputo, Jean, Rodenhuis, Sjoerd, Peters, William P., Leonard, Robert C., Barlow, William E., Tallman, Martin S., Bergh, Jonas, Nitz, Ulrike A., Gianni, Alessandro M., Basser, Russell L., Zander, Axel R., Coombes, R. Charles, Roché, Henri, Tokuda, Yutaka, de Vries, Elisabeth G.E., Hortobagyi, Gabriel N., Crown, John P., Pedrazzoli, Paolo, Bregni, Marco, Demirer, Taner
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4322115/
https://ncbi.nlm.nih.gov/pubmed/21768471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.5910
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados